logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences CEO talks expansion into CAR-T therapy with novel proprietary approach

Tiziana Life Sciences PLC's (LON:TILS) (NASDAQ:TLSA) CEO Dr Kunwar Shailubhai speaks to Proactive London's Andrew Scott after announcing they've submitted a patent application that could help unlock the true potential of a promising form of cancer immunotherapy. Tiziana wants to use Foralumab, its fully human anti-CD3 monoclonal antibody, to improve the success of CAR-T therapy, which uses T cells from the patient’s own immune system to tackle the disease.

Quick facts: Tiziana Life Sciences PLC

Price: 168 GBX

AIM:TILS
Market: AIM
Market Cap: £320.14 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences PLC's clinical plan is shaping up says analyst Emma Ulker

Proactive Research analyst Emma Ulker says Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) is driving forwards at speed with the clinical development plan for its fully-human mAb TZLS-501 COVID-19 treatment. She adds that with GMP-grade manufacturing already underway they've appointed a number...

1 week, 3 days ago

2 min read